RxDoctor Payments Data

Stacey Hall, NP

Nurse Practitioner · Lebanon, TNNPI 1760950547

Payments from drug & device makers

$9,614in general payments, 2019–2025

Across 394 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$801
  • Johnson & Johnson$718
  • Teleflex LLC$615
  • AbbVie$594
  • Sumitomo Pharma America, Inc.$576
  • plus $5K from 36 others

What the payments were for

  • Travel & lodging$4635%
  • Food & beverage$8,92193%
  • Education$2302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,614 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$123,436
Medicare patients
773
Services billed
4,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron249$200,128
GemtesaVibegron124$110,427
Methenamine Hippurate292$23,512
PremarinEstrogens, Conjugated45$20,081
Solifenacin Succinate178$14,517
Estradiol99$6,118
Tolterodine Tartrate ErTolterodine Tartrate36$4,896
Trospium Chloride ErTrospium Chloride30$4,017
Tamsulosin Hcl325$3,605
Testosterone13$3,384
Fosfomycin Tromethamine17$3,374
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst110$2,508
Oxybutynin Chloride ErOxybutynin Chloride87$1,817
Potassium Citrate ErPotassium Citrate26$1,786
Bethanechol Chloride11$1,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$801$200,128249 claims
Sumitomo Pharma America, Inc.Gemtesa$576$110,427124 claims
PfizerPremarin$377$20,08145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Lebanon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →